FORECASTS: Merck's revenue expected to grow in Q2, but a deal will weigh

{
  "signal_id": "377b29a9-dfa6-b2d5-546b-eda029f62b22",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-08-03T19:21:28+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.boursorama.com/bourse/actualites-amp/previsions-le-chiffre-d-affaires-de-merck-devrait-progresser-au-deuxieme-trimestre-mais-un-accord-pesera-sur-le-resultat-net-6364168570f9f62347ad075eb998dae4",
    "title": "FORECASTS: Merck's revenue expected to grow in Q2, but a deal will weigh - Boursorama",
    "excerpt": "((Automated translation by Reuters using machine learning and generative AI, please refer to the following disclaimer: https://bit.ly/rtrsauto)) August 3 - ** Shares of pharmaceutical company Merck & Co MRK.N fell 1.9% in the last session, ahead of its quarterly results scheduled for release on Tuesday before market open ** Wall Street expects MRK, provider of the successful immunotherapy cancer treatment Keytruda, to report an adjusted loss per share of $0.27 in the second quarter, compared to earnings per share of $2.19 in the same quarter last year, on revenue of $16.36 billion, up approximately 3.5% from $15.81 billion recorded a year ago – LSEG data ** The results are expected to include a charge of approximately $2.35 per share related to MRK's completion of the acquisition of biotechnology company Terns Pharma, announced in March for $6.7 billion, as the company seeks to strengthen its oncology product portfolio ahead of Keytruda's patent expiration later in the decade. ** Over the past eight quarters, MRK's revenue has exceeded analysts' forecasts seven times, while EPS has beaten forecasts every time ** The stock last traded at $127.76 against a median price target of $137, according to data compiled by LSEG, which lists 32 analyst recommendations: eight \"strong buy\", 14 \"buy\" and 10 \"hold\" ** Year-to-date, the stock has gained approximately 21%, compared to a rise of...",
    "summary": "Merck & Co. completed its acquisition of biotechnology company Terns Pharma for $6.7 billion, a deal announced in March to bolster its oncology portfolio.",
    "planning": false,
    "image_url": "https://www.boursorama.com/bundles/boursoramaui/images/news/trading-news-2.jpg",
    "confidence": 0.9,
    "published_at": "2026-08-03T19:21:28Z",
    "article_sentence": "The results are expected to include a charge of approximately $2.35 per share related to MRK's completion of the acquisition of biotechnology company Terns Pharma, announced in March for $6.7 billion, as the company seeks to strengthen its oncology product portfolio ahead of Keytruda's patent expiration later in the decade.",
    "amount_normalized": 6700000000,
    "related_company_name": "Terns Pharma",
    "related_company_domain": "ternspharma.com"
  }
}

curl https://signals.autobound.ai/v1/signals/377b29a9-dfa6-b2d5-546b-eda029f62b22 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","limit":20}'